Form 8-K - Current report:
SEC Accession No. 0001171843-25-004118
Filing Date
2025-06-26
Accepted
2025-06-26 07:30:59
Documents
13
Period of Report
2025-06-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_062625.htm   iXBRL 8-K 25852
2 EXHIBIT 10.1 exh_101.htm EX-10.1 223098
  Complete submission text file 0001171843-25-004118.txt   452752

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE aps-20250620.xsd EX-101.SCH 3026
4 XBRL LABEL FILE aps-20250620_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE aps-20250620_pre.xml EX-101.PRE 22367
15 EXTRACTED XBRL INSTANCE DOCUMENT f8k_062625_htm.xml XML 3596
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 251075068
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)